Correlation Between Karyopharm Therapeutics and Entrada Therapeutics

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Entrada Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Entrada Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Entrada Therapeutics, you can compare the effects of market volatilities on Karyopharm Therapeutics and Entrada Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Entrada Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Entrada Therapeutics.

Diversification Opportunities for Karyopharm Therapeutics and Entrada Therapeutics

0.14

Correlation Coefficient

Karyopharm Therapeutics  Entrada Therapeutics

Average diversification

The 3 months correlation between Karyopharm and Entrada is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Entrada Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entrada Therapeutics and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Entrada Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entrada Therapeutics has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Entrada Therapeutics go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Entrada Therapeutics

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Entrada Therapeutics. In addition to that, Karyopharm Therapeutics is 1.46 times more volatile than Entrada Therapeutics. It trades about -0.2 of its total potential returns per unit of risk. Entrada Therapeutics is currently generating about 0.02 per unit of volatility. If you would invest  1,737  in Entrada Therapeutics on September 26, 2024 and sell it today you would earn a total of  19.00  from holding Entrada Therapeutics or generate 1.09% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Entrada Therapeutics

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Entrada Therapeutics

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Entrada Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady fundamental indicators, Entrada Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Karyopharm Therapeutics and Entrada Therapeutics

The main advantage of trading using opposite Karyopharm Therapeutics and Entrada Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Entrada Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entrada Therapeutics will offset losses from the drop in Entrada Therapeutics' long position.

The idea behind Karyopharm Therapeutics and Entrada Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.